AquaBounty Technologies, Inc. (AQB)
1.11
+0.01
(+0.91%)
USD |
NASDAQ |
Oct 16, 16:00
1.09
-0.02
(-1.80%)
After-Hours: 20:00
AquaBounty Technologies Net Income (Quarterly) : -1.332M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.332M |
| March 31, 2026 | -0.9248M |
| December 31, 2025 | 2.033M |
| September 30, 2025 | -1.484M |
| June 30, 2025 | -1.200M |
| March 31, 2025 | 0.8379M |
| September 30, 2024 | -2.638M |
| June 30, 2024 | -30.53M |
| March 31, 2024 | -2.710M |
| December 31, 2023 | -8.425M |
| September 30, 2023 | -6.138M |
| June 30, 2023 | -6.509M |
| March 31, 2023 | -6.486M |
| December 31, 2022 | -6.069M |
| September 30, 2022 | -5.440M |
| June 30, 2022 | -5.536M |
| March 31, 2022 | -5.112M |
| December 31, 2021 | -6.068M |
| September 30, 2021 | -6.865M |
| June 30, 2021 | -5.231M |
| March 31, 2021 | -4.159M |
| December 31, 2020 | -6.117M |
| September 30, 2020 | -3.650M |
| June 30, 2020 | -3.524M |
| Date | Value |
|---|---|
| March 31, 2020 | -3.110M |
| December 31, 2019 | -3.419M |
| September 30, 2019 | -3.018M |
| June 30, 2019 | -4.027M |
| March 31, 2019 | -2.764M |
| December 31, 2018 | -2.424M |
| September 30, 2018 | -2.727M |
| June 30, 2018 | -2.781M |
| March 31, 2018 | -2.450M |
| December 31, 2017 | -2.663M |
| September 30, 2017 | -2.446M |
| June 30, 2017 | -2.093M |
| March 31, 2017 | -2.056M |
| December 31, 2016 | -2.446M |
| September 30, 2016 | -2.142M |
| June 30, 2016 | -2.064M |
| March 31, 2016 | -1.819M |
| December 31, 2015 | -1.838M |
| September 30, 2015 | -1.658M |
| December 31, 2014 | -1.618M |
| September 30, 2014 | -2.032M |
| June 30, 2014 | -1.890M |
| March 31, 2014 | -1.587M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Agenus, Inc. | -0.567M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Amgen, Inc. | 2.375B |
| Anika Therapeutics, Inc. | 3.309M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 1.332M |
| EPS Diluted (Quarterly) | -0.3169 |
| Enterprise Value | 3.828M |
| Earnings Yield | -412.8% |
| Normalized Earnings Yield | -432.59 |